Condition
Lung Large Cell Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownTesting the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerNCT05198830 · 2022-12-15
ACTIVE_NOT_RECRUITINGVeliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01386385 · 2011-06-20
ACTIVE_NOT_RECRUITINGCombination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT00334815 · 2006-06-15
ACTIVE_NOT_RECRUITINGCommon interventions
CarboplatinDRUG2CisplatinDRUG2Radiation TherapyRADIATION23-Dimensional Conformal Radiation TherapyRADIATION1BevacizumabBIOLOGICAL1Computed TomographyPROCEDURE1DocetaxelDRUG1DurvalumabBIOLOGICAL1EtoposideDRUG1FDG-Positron Emission TomographyPROCEDURE1FilgrastimBIOLOGICAL1Laboratory Biomarker AnalysisOTHER1Magnetic Resonance ImagingPROCEDURE1MethoxyamineDRUG1PaclitaxelDRUG1PegfilgrastimBIOLOGICAL1PemetrexedDRUG1Placebo AdministrationOTHER1VeliparibDRUG1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
Phase mix
PHASE23
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.